LSTA — LISATA THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 320017 ·
Last close
$1.04
Market Cap
$11.24M
52W High
$5.07
52W Low
$0.96
ADV30
139,040
Next earnings
2026-11-05
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -10,030,000 -6,787,000 648,410,000 282,717,000 640,767,000
Jun 2026 0 — -3,992,000 -2,929,000 11,027,000 10,443,000 3,037,000
Mar 2026 0 — -4,942,000 -4,489,000 14,059,000 13,060,000 3,387,000
Dec 2025 100,000 — -3,079,000 -2,954,000 17,744,000 15,956,000 3,143,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-12,323,000
Investing CF
$5,150,000
Financing CF
$768,000
CapEx
$-28,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.85
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-572,070,000
Inventory
—
Receivables
$0
ST Investments
$0
EBIT TTM
$-16,427,000
Pretax Income TTM
$-15,008,000
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$100,000
EBITDA
$-16,362,000
Free Cash Flow
$-8,100,250
Enterprise Value
$206,233
Total Cash
$10,443,000
Total Debt
$0
Shares Out
10,804,066
Trailing EPS
$-1.64
Book Value
$1.68
ROE
-101.7%
ROA
-56.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 170,000 -18,209,000 -16,586,000 17,744,000 3,143,000 14,855,000 -15,949,000
Dec 2024 1,000,000 -22,409,000 -19,985,000 35,002,000 5,685,000 29,571,000 -19,356,000
Dec 2023 0 -25,708,000 -20,840,000 54,694,000 6,800,000 48,148,000 -20,032,000
Dec 2022 0 -57,601,000 -54,225,000 73,034,000 6,710,000 66,578,000 -21,170,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$100,000
NetIncome TTM
$-14,621,000
OpCashFlow TTM
—
Assets (Latest)
$11,027,000
Forward EPS
$-1.16

Peers — same industry

TickerNameMarket CapLastDaily %
ASBP Aspire-Lakewood Holdings, Inc. $11.64M $8.30 —
HIND Vyome Holdings, Inc $10.84M $1.54 —
CMMB Chemomab Therapeutics Ltd. $12.02M $1.64 —
OPTH Optimi Health Corp. $12.02M $2.10 —
HEPA Hepion Pharmaceuticals, Inc. $10.38M $0.12 —

News headlines (Yahoo Finance, 1h cache)

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-B
2026-11-09 14:00 · Yahoo
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
2026-11-05 13:30 · Yahoo
Lisata adds biopharma finance veteran Jeffrey Farrow to board
2026-10-15 12:41 · Yahoo
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
2026-10-14 20:05 · Yahoo
Lisata Therapeutics wins new US patent for pancreatic cancer drug
2026-10-08 13:10 · Yahoo
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
2026-10-08 12:00 · Yahoo
Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
2026-10-05 13:43 · Yahoo
MARKETS LIVE: Nasdaq hits record high as tech stocks lead Wall Street higher
2026-10-05 11:03 · Yahoo
Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
2026-09-24 12:55 · Yahoo
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
2026-09-24 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.